半剂量瑞替普酶联合瑞舒伐他汀对急性ST段抬高型心肌梗死患者凝血状态的影响

doi:10.3969/j.issn.1671-7171.2018.06.027

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of half-dose reteprase combined with resuvastatin on coagulation status in patients with acute ST-segment elevation myocardial infarction (STEMI).【Methods】A total of 86 patients with acute STEMI admitted in our hospital from October 2016 to October 2017 were randomly divided into two groups: control group (nong43, half dose of reteprase) and observation group (nyang43, half-dose of reteprase combined with resuvastatin), and the cardiac function of the two groups was observed. Coagulation factor and serum factor.【Results】After treatment, left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) in the observation group were significantly lower than those in the control group (P<0.05), and the cardiac output (SV) and left ventricular ejection fraction (LVEF) were significantly higher in the observation group than in the control group (P<0.05). After treatment, the levels of hs-CRP, homocysteine (Hcy) and complement 3 (C3) in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) in the observation group were significantly longer than those in the control group (P<0.05), and the level of fibrinogen (FIB) was significantly lower than that in the control group (P<0.05).【Conclusion】Half-dose reteprase combined with resuvastatin in the treatment of acute STEMI can effectively improve the cardiac function and coagulation function of the patients, and reduce the level of serum hs-CRP,Hcy and C3in patients with acute STEMI.

Key words： MyocardialInfarction/TH AcuteDisease Hydroxymethylglutaryl-CoAReductaseInhibitors/AD TissuePlasminogenActivator/AD BloodCoagulation

Received: 14 March 2018

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2018.06.027 OR http://www.jcr.net.cn/EN/Y2018/V35/I6/1124

[1] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.2105急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2015, 43(5):675-690.
[2] 沈卫峰, 张奇, 张瑞岩. 2015年急性ST段抬高型心肌梗死诊断和治疗指南解析[J]. 国际心血管病杂志, 2015, 42(4):217-219.
[3] 李云. 常规剂量替罗非班联合半剂量瑞替普酶治疗ST段抬高性急性心肌梗死的疗效观察[J]. 实用临床医药杂志, 2016, 20(1):20-22.
[4] Kaya A, Kurt M, Tanboga IH, et al. Rosuvastatin versus Atorvastatin to prevent Contrast Induced Nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-CIN trial)[J]. Acta Cardiol, 2013, 68(5):489.
[5] 王庭学, 吴国平, 梁毓源. 常规剂量替罗非班联合半剂量瑞替普酶对急性STEMI的疗效[J]. 心血管康复医学杂志, 2016, 25(3):308-311.
[6] 张守文, 王彩虹, 王洁,等. 急性ST段抬高心肌梗死患者半量瑞替普酶溶栓后行易化经皮冠状动脉介入治疗的疗效评价[J]. 中国介入心脏病学杂志, 2015, 23(4):217-220.
[7] 刘杨. 老年急性ST段抬高型心肌梗死患者急诊PCI术后应用瑞舒伐他汀与阿托伐他汀的疗效对比[J]. 实用临床医药杂志, 2015, 19(17):142-144.
[8] 赵明, 张军, 张巍,等. 术前强化阿托伐他汀治疗对急性ST段抬高型心肌梗死患者的疗效探讨[J]. 中国医药导刊, 2014(7):1153-1154.
[9] Aydin MU, Aygul N, Altunkeser BB, et al. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction[J]. Atherosclerosis, 2015, 239(2):439-443.
[10] 戴树人, 李芝峰, 廖荣宏,等. 替罗非班联合瑞替普酶在ST 段抬高性急性心肌梗死中的疗效观察[J]. 重庆医学, 2014,43(21):2720-2721.
[11] 李平, 黄翠娟, 甘剑挺,等. 负荷量瑞舒伐他汀对急性ST段抬高型心肌梗死急诊介入治疗患者的影响[J]. 中国临床药理学杂志, 2013, 29(10):732-735.